Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan vs T-DM1 in HER2-Positive Metastatic Breast Cancer
NCT03529110Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Aug 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03529110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529110.